More Details

This is a study to investigate the effectiveness of ALLO to regenerate the brain in persons with mild Alzheimer’s. Study participants will be randomly assigned to receive an intravenous infusion of either ALLO or placebo weekly for 12 months. After 12 months, all participants will receive ALLO for the remaining 6 months. This means that for the last 6 months of the study, all of those who were receiving ALLO will continue to receive ALLO, and all those who received placebo will be switched to ALLO treatment. Study procedures include physical and neurological examinations, electrocardiogram (ECG), blood and urine laboratory tests, brain Magnetic Resonance Imaging (MRI) scans, intravenous infusion for 30 minutes once per week and health questionnaires and assessments that you and your caregiver will complete.

To participate in this study all patients must have the APOE ε4 gene, a risk factor for Alzheimer’s Disease. For more information on this gene and genetic testing please visit our genetic counseling information page.